Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MEDI2070 in moderate to severe Crohn's disease after anti-TNF-alpha failure
2012-004098-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing MEDI2070 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2013; status: completed.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2012-004098-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004098-26.